Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saby George

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
The Lancet. Oncology|March 5, 2019
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort studyNieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
The Lancet. Oncology|March 5, 2019
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort studyNieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, et al.
Pageof 10